Therapeutic efficacy of imatinibmesilate (glivek) in chronic phase of myeloid leukemia
- 作者: Turkina A1, Khoroshko N1, Druzhkova G1, Zingerman В1, Zakharova E1, Chelysheva E1, Vmogradova O1, Domracheva E1, Zakharova A1, Kovaleva L1, Kolosheinova T1, Kolosova L1, Zkuravleva V1, Tikhonova L1
-
隶属关系:
- ГНЦ РАМН, Москва
- 期: 卷 78, 编号 8 (2003)
- 页面: 62-68
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33388
- ID: 33388
如何引用文章
全文:
详细
failed interferon-alpha (If-a) preparations.
Material and methods. 79 patients in a chronic phase of Ph+CML with hematological and cytogenetic
resistance or intolerance of If-a. The response to glivec was assessed by achievement of a complete
hematological remission and the cytogenetic effect (the degree of reduction of cell clone Ph+ in bone
marrow). Tolerance and safety of the drug was studied by monthly standard clinicohematological tests.
Results. Not only a hematological remission (92.4%), but also partial (46.8%) or complete (27.8%)
elimination of BCR-ABL±cells were achieved after 12 months of the treatment. Glivec was well tolerated.
Hematological toxicity primarily as neutropenia and thrombocytopenia were observed in 54.4
and 42% patients, respectively. Neutropenia of the third degree which made impossible to continue the
treatment was observed in 29.1% patients; throbocytopenia of the third degree was registered in 16.5%
patients. Among most frequent поп-hematological side effects there were moderate edema, nausea, leg
muscle convulsions, weight gain, arthralgias, skin eruption. All the complications were transient, were
managed in all cases with only a short-time discontinuation of glivec therapy.
Conclusion. High activity of glivec at early stages of CML allows using this drug as a first-line therapy
in patients with CML
作者简介
A Turkina
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
N Khoroshko
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
G Druzhkova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
В Zingerman
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
E Zakharova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
E Chelysheva
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
O Vmogradova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
E Domracheva
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
A Zakharova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
L Kovaleva
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
T Kolosheinova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
L Kolosova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
V Zkuravleva
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
L Tikhonova
ГНЦ РАМН, МоскваГНЦ РАМН, Москва
参考
- Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia giemsa starting. Nature 1973; 243: 290-303.
- Gordon M. Y. Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment. Br. J. Haematol. 1996; 95: 10-20.
- Druker B. J., Lydon N. B. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myeloid leukemia. J. Clin. Invest. 2000; 105: 3-7.
- Deininger M. V., Goldman G. J., Lydon N., Melo J. V. The tyrosine kinase inhibitor CGP571148 В selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90: 3691- 3698.
- Kantarjian H. M., O'Brien S., Anderini P., Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigation options. J. Am. Soc. Hematol. 1996; 87 (8): 3069- 3080.
- Allan N. C., Richards S. M., Sheperd P. С. A et al. UK Medical Research Council randomised multicentre trial of interferon-cc in chronic myeloid leukaemia: improved servival irrespective of cytogenetic response. Lancet 1995; 345: 1392- 1397.
- Kantarjian H. M., Francis J., O'Brien S., Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and hemotherapy. Hematol./Oncol. Clin. N. Am. 1998; 12 (1): 31-79.
- Druker B. J., Talpaz M., Debra J. et al. Efficacy and safety of specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. J. Med. 2001; 344 (14): 1031 - 1037.
- Kantarjian H., Sawyers C. L., Hochhaus A. et al. Phase 11 study of STI571 in patients with resistance or refractory Philadelphia chromosome positive chronic myeloid leukemia. Blood 2000; 96: 470a.
- Talpaz M., Kautarjian H. M., McCredie К. В. et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N. Engl. J. Med. 1986; 314: 1065-1069.
- Юнис Дж. Дж. В кн. Современная гематология и онкология. М.: Медицина; 1987. 351-390.
- Pinkel D., Straume Т., Gray У. W., Proc. Natl. Acad. Sci., USA 1986; 2934-2938.
- Kobzev Y. N., Domracheva E. V., Zakharova A. V. et al. Cancer Genet. Cytogenet. 1998; 106: 128-134.
- Kantarjian H. M., Smith T. L., McCredie К. В. et al. Chronic myelogenous leukemia: a multivariate analysis of the association patient characteristics and therapy with survival. Blood 1985; 66: 1326-1335.
- Хорошко Н. Д. Современная терапия хронического миелолейкоза: Автореф. дис. ... д-ра мед. наук. М.; 1992.
- Туркина А. Г. Клиническое значение молекулярно-генетических и иммунофенотипических характеристик хронического миелолейкоза: Автореф. дис. д-ра мед. наук. М.; 1998.
- Хорошко Н. Д., Туркина А. Г., Кузнецов С. В. и др. Хронический миелолейкоз - успехи современного лечения и перспективы. Гематол. и трансфузиол. 2001; 4: 7-12.
- Talpaz V., Silver R. Т., Druker В. J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99 (6): 1928-1937.
- Kantarjian H. M., O'Brien S., Cortes J. Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesilate (STI571). In: Hematology. Orlando, Florida; 2001; abstr. 594.
- Druker B. J., Charles L., Saviers С L. Activity of specific inhibitor of BCR-ABL tyrosin kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001; 344: 1038-1042.
- Михайлова И. Н. Клинико-иммунофенотипическая характеристика бластного кризахронического миелолейкоза: Автореф. дис. ... канд. мед. наук. М.; 1995.
- Larson R. On behaf of IRIS Imatinib (STI571 Glivec) as initial therapy for patients with newly Ph+ chronic myelod leukemia (CML): results of a randomized phase III study vs interferon +Ara-C in). Blood 2002; 100 (11): 48